Gefitinib versus Erlotinib as First-line Treatment of Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in Chaophrayayommarat Hospital, A Survival Analysis Study
- Conditions
- Efficacy of 2 first-generation EGFR TKIs, gefitinib versus erlotinib, in patients with EGFR mutated advanced non-small cell lung cancer.GefitinibErlotinibEGFR mutationNon-small cell lung cancer
- Registration Number
- TCTR20231002008
- Lead Sponsor
- Chaoprayayommarat Hospital Research Ethical Committee
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 256
Inclusion Criteria
1.Age more than 15 years old
2.Histology or cytology confirmed diagnosis of non-small cell lung cancer stage 3B or 4.
3.Received first line treatment with gefitinib or erlotinib.
4.Have at least 1 time of radiologic assessment
Exclusion Criteria
Can not tolerated or denied receiving gefitinib or erlotinib until disease progression.
Received surgery/Radiotherapy/chemotherapy during treatment with gefitinib or erlotinib.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival at the end of study Progression free survival
- Secondary Outcome Measures
Name Time Method Overall survival at the end of study Overall survival